# Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

> **NCT02105454** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 79 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Grazoprevir (GZR)
- **DRUG:** Elbasvir (EBR)
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT02105454
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-23
- **Primary completion:** 2015-05-04
- **Final completion:** 2015-05-04
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02105454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02105454, "Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02105454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*